4d biomaterials investment

Capital deployed:

  • £690,000 EIS qualifying

Uses of funds:

  • Further development of technology
  • Continued commercialisation of range of resin-ink products
  • Expansion of team

visit the website

4D Biomaterials is the developer of 4Degra™, a new class of innovative 3D printing resin-inks. The business supplies unique materials which enable its customers to create biocompatible, biodegradable and bioresorbable medical devices designed to promote tissue regeneration across a range of applications.

4D Biomaterials spun out of the University of Warwick and University of Birmingham in 2020 following 15 years of research and development in founder Professor Andrew Dove’s research group. The business has since brought on board CEO Phil Smith, an entrepreneur with a track record in commercialising university research in successful spin-outs. The team is based at its lab in MediCity, Nottingham.

DSW Ventures made a £690,000 EIS qualifying investment in July 2021 as part of a £1.6 million raise alongside co-investors Mercia. The funding will support further investment into the technology and its commercialisation through continued R&D and new hires.



Key Contacts:

keith bensonDavid SmithEllie Boardman
Keith BensonDavid SmithEllie Boardman